A Randomized, Single-blind, Parallel Group ,Phase II Clinical Trial to Compare ReJoinTM (Autologous Adipose-derived Mesenchymal Progenitor Cells)to Sodium Hyaluronate Injection for the Patients With Knee Osteoarthritis Cartilage Defects

Trial Profile

A Randomized, Single-blind, Parallel Group ,Phase II Clinical Trial to Compare ReJoinTM (Autologous Adipose-derived Mesenchymal Progenitor Cells)to Sodium Hyaluronate Injection for the Patients With Knee Osteoarthritis Cartilage Defects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Cartilage disorders; Osteoarthritis; Sports injuries
  • Focus Therapeutic Use
  • Sponsors Cellular Biomedicine Group
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2016 According to a Cellular Biomedicine Group's media release, the company plan to release results from this trial in the first half of 2017.
    • 08 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top